Evidence map›Paper›PMID 28848898›Full record

ArticleChronic obstructive pulmonary diseases (Miami, Fla.)2016

Long-Term Maintenance Bronchodilation With Indacaterol/Glycopyrrolate Versus Indacaterol in Moderate-to-Severe COPD Patients: The FLIGHT 3 Study.

Gary T Ferguson, Angel Fowler Taylor, Chau Thach, Qian Wang, Agnes A Schubert-Tennigkeit, Francesco Patalano, Donald Banerji

Abstract read
In one paragraph

Article in Chronic obstructive pulmonary diseases (Miami, Fla.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review.International journal of chronic obstructive pulmonary disease
    Pooled it
  4. Review
  5. Article
  6. Article
  7. Dual Bronchodilator in the Era of Triple Therapy.International journal of chronic obstructive pulmonary disease · 2020
    Review
  8. Review
  9. Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease.International journal of chronic obstructive pulmonary disease · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Gary T FergusonPulmonary Research Institute of Southeast Michigan-Farmington Hills.
Angel Fowler TaylorNovartis Pharmaceuticals Corporation, East Hanover, New Jersey.
Chau ThachNovartis Pharmaceuticals Corporation, East Hanover, New Jersey.
Qian WangBeijing Novartis Pharma Co. Ltd., Shanghai, China.
Agnes A Schubert-TennigkeitNovartis Pharma AG, Basel, Switzerland.
Francesco PatalanoNovartis Pharma AG, Basel, Switzerland.
Donald BanerjiNovartis Pharmaceuticals Corporation, East Hanover, New Jersey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

chronic obstructive pulmonary diseaseclinical trialscopdlong-acting beta2-agonistslong-acting muscarinic antagonist

Identifiers

PMID28848898
PMCPMC5556955

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.